Loading
Hofseth BioCare ASA Stock: price and insider trades · Norway
1 insider bought €261k of shares over the last 90 days, the latest filed 17 Sept 2026.
Hofseth BioCare ASA: what insiders have been doing
Every trade that managers of Hofseth BioCare ASA disclose to Oslo Børs is tracked on this page. The company sits in the Health Care sector. The last twelve months, up to 18 October 2026, brought 4 filings signed by 3 insiders.
Every open-market trade in the period is a purchase: 1 purchase worth €261k, from 1 insider, and not a single sale. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. The largest single trade was a purchase of €261k by Christoph Baldegger, published on 17 September 2026, equal to 0.40% of the market capitalisation.
For context, the typical company on the same exchange (median of 257 companies) published 4 filings over the same period, against 4 filings here. The full history, which starts in 2021, counts 6 purchases against no sales.
The clock since the last published purchase (17 September 2026) now reads 30 days.
Other companies in the same sector with recent insider buying flagged by our signals: MAIA Biotechnology, Inc. and Cooper Companies, Inc. These figures are compiled from regulatory filings published by Oslo Børs. They describe what insiders did and are not a recommendation.
Insider Decl.
23
Thresholds
n/a
Buy Volume
€409,740
6 ops. · all time
Sell Volume
n/a
n/a
Who traded when
BuySaleChristoph Baldegger1 buy
Since the insiders bought
- -23.4%Entry NOK 3.37 · Close at T+365 NOK 2.58
- -13.8%Entry NOK 3.83 · Close at T+365 NOK 3.30
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Fundamental score
Ranked 21,744 of 24,148 companies
22.2
score / 100
Value15
Quality29
FCF yld-7.2%
Earn yld-20%
EV/EBITDA·
ROE·
Gross mgn37%
Net mgn-53%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
NOK 1.38
Analyst consensus
Income statement
RevenueNOK 256.3M
Gross profitNOK 95.4M37% margin
EBITDA-NOK 72.6M-28% margin
Net income-NOK 134.9M-56.4% margin
Valuation
Beta0.25
Balance sheet & cash
Market capNOK 696.1M
Total debtNOK 359.9M
Free Cash Flow-NOK 48.3M
Profitability & ownership
ROA-17.6%
% insiders39.2%
% institutions13.0%
Last declaration on 17 September 2026
Declarations23 total
2,500,000 shares@ NOK 1.130.40% mcap60.2% of flowShareXOSLOSLO:682649
Canonical exit: 16 Dec 2026 (T+90)
30,384,615 shares@ NOK 1.305.29% mcap100.0% of flowShareXOSLOSLO:677269
ShareXOSLOSLO:660280
ShareXOSLOSLO:657989
ShareXOSLOSLO:639377
700,000 shares@ NOK 1.202816.6% of flowShareXOSLOSLO:634586
@ €0.2389ShareXOSLOSLO:605026
74,000 shares@ NOK 2.70100.0% of flowShareXOSLOSLO:595384
200,000 shares@ NOK 2.69100.0% of flowShareXOSLOSLO:583781
100,000 shares@ NOK 2.7256.2% of flowShareXOSLOSLO:582822
24,000 sharesShareXOSLOSLO:582560
70,000 shares@ NOK 2.90243.8% of flowOptionXOSLOSLO:579387
Canonical exit: 29 Mar 2023 (T+90)
ShareXOSLOSLO:567179
ShareXOSLOSLO:566342
45,000 shares@ NOK 3.776413.2% of flowShareXOSLOSLO:561410
Canonical exit: 3 Aug 2022 (T+90)
ShareXOSLOSLO:560704
50,000 shares@ NOK 7.420328.1% of flowShareXOSLOSLO:550222
Canonical exit: 21 Mar 2022 (T+90)
55,000 shares@ NOK 7.256231.2% of flowShareXOSLOSLO:547291
Canonical exit: 15 Feb 2022 (T+90)
30,000 shares@ NOK 6.7901100.0% of flowOptionXOSLOSLO:543659
50,000 shares@ NOK 7.3227.6% of flowShareXOSLOSLO:541135
Canonical exit: 27 Nov 2021 (T+90)
50,000 shares@ NOK 7.72958.7% of flowShareXOSLOSLO:534028
70,000 shares@ NOK 9.29414.5% of flowShareXOSLOSLO:523929
23 of 23 declarations
About Hofseth BioCare ASA
Hofseth BioCare ASA is a Norwegian company operating in the health and pharmaceutical sector. It focuses on the development and commercialization of products derived from marine biomass.
